Skip to main content

Site notifications

Notice for sabizabulin (Adjutor Healthcare Pty Ltd)

Active ingredients
Date of review outcome
Lapse date
Provisional determination
For treatment of SARS-CoV-2 infection in hospitalised patients with moderate to severe COVID-19 infection who are at high risk for Acute Respiratory Distress Syndrome (ARDS).
Therapeutic area
Infectious diseases

Help us improve the Therapeutic Goods Administration site